We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 02, 2022

Exploring Deubiquitylase OTUD6B as a Potential Therapeutic Strategy for ccRCC With VHL Mutations

Cell death & disease


Additional Info

Disclosure statements are available on the authors' profiles:

Cell death & disease
Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma
Cell Death Dis 2022 Feb 02;13(2)97, K Guo, Y Wei, Z Wang, X Zhang, X Zhang, X Liu, W Wu, Z Wu, L Zhang, CP Cui

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading